tiprankstipranks
Nabriva Therapeutics (NBRVF)
OTHER OTC:NBRVF
US Market

Nabriva Therapeutics (NBRVF) Income Statement

Compare
1,018 Followers

Nabriva Therapeutics Income Statement

Last quarter (Q2 2023), Nabriva Therapeutics's total revenue was $2.57M, a decrease of -70.67% from the same quarter last year. In Q2, Nabriva Therapeutics's net income was $-12.06M. See Nabriva Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 35.67M$ 27.22M$ 2.86M$ 7.75M$ 6.50M
Gross Profit
$ 7.09M$ 14.07M$ 2.10M$ 7.68M$ 6.50M
Operating Expenses
$ 62.58M$ 62.60M$ 68.22M$ 87.17M$ 120.88M
Depreciation and Amortization
$ 217.00K$ 637.00K$ 820.00K$ 770.00K$ 510.00K
EBITDA
$ -54.70M$ -47.42M$ -64.85M$ -78.72M$ -114.09M
Operating Income
$ -55.49M$ -48.53M$ -66.13M$ -79.49M$ -114.38M
Other Income/Expenses
$ -127.00K$ -432.00K$ -3.22M$ -3.17M$ -356.00K
Pretax Income
$ -55.62M$ -48.96M$ -69.34M$ -82.66M$ -114.73M
Net Income
$ -57.19M$ -49.45M$ -69.48M$ -82.76M$ -114.78M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -21.32$ -28.52$ -135.23$ -278.86$ -564.91
Diluted EPS
$ -21.32$ -28.52$ -135.23$ -278.86$ -564.91
Weighted Average Shares Outstanding
2.68M 1.73M 513.80K 296.80K 203.18K
Weighted Average Shares Outstanding (Diluted)
2.68M 1.73M 513.80K 296.80K 203.18K
Currency in USD

Nabriva Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis